Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
Pediatr Blood Cancer. 2023 Oct;70(10):e30596. doi: 10.1002/pbc.30596. Epub 2023 Jul 21.
Pediatric differentiated thyroid cancers (DTCs) differ in pathophysiology, presentation, and clinical outcomes from adult DTCs. However, the cutoff age for defining pediatric DTCs remains debatable, with the American Thyroid Association (ATA) and International Incidence of Childhood Cancer (IICC) report recommending different cutoffs of 18 and 14 years, respectively. In this study, we investigated the appropriateness of 14-year cutoff by comparing the clinical characteristics and long-term outcomes in the 14 years and younger and 15-18 years age groups.
Data of DTC patients, aged 18 years and older, from 1981 to 2016, were sequentially extracted and compared between two age groups: ≤14 and 15-18 years.
Total of 176 pediatric DTC patients were included (age group ≤14 years: n = 75; age group 15-18 years: n = 101). None of the baseline clinical characteristics were significantly different between the two age groups. At 2-year follow-up, patients in the age group ≤14 years had significantly higher incomplete response rate compared to those in the age group 15-18 years (69% vs. 42%, respectively, p < .001). However, over a median follow-up of 10.6 years (interquartile range: 7.7-15.5), the 5- and 10-year Disease-free survival (DFS) probabilities were not significantly different (p = .406). On multivariate analysis, incomplete response at 2-year follow-up was the sole independent predictor of poor DFS (hazard ratio: 5.85, 95% confidence interval: 1.69-20.23).
Subdivision of pediatric DTCs into less than or equal to 14 years and 15-18 years age groups did not have any long-term predictive value. The cutoff of 18 years as recommended by ATA is reasonable and should be uniformly followed to avoid inconsistencies and confusion.
儿科分化型甲状腺癌(DTC)在病理生理学、表现和临床结局方面与成人 DTC 不同。然而,定义儿科 DTC 的年龄截止点仍存在争议,美国甲状腺协会(ATA)和国际儿童癌症发病率(IICC)报告分别建议使用 18 岁和 14 岁作为截止点。在这项研究中,我们通过比较 14 岁及以下和 15-18 岁年龄组的临床特征和长期结果,研究了 14 岁截止点的合理性。
从 1981 年至 2016 年,连续提取年龄在 18 岁及以上的 DTC 患者的数据,并在两个年龄组(≤14 岁和 15-18 岁)之间进行比较。
共纳入 176 例儿科 DTC 患者(年龄组≤14 岁:n=75;年龄组 15-18 岁:n=101)。两个年龄组之间的基线临床特征均无显著差异。在 2 年随访时,年龄组≤14 岁的患者不完全缓解率显著高于年龄组 15-18 岁的患者(分别为 69%和 42%,p<0.001)。然而,在中位数为 10.6 年(四分位间距:7.7-15.5)的随访中,5 年和 10 年无病生存率(DFS)无显著差异(p=0.406)。多因素分析显示,2 年随访时的不完全缓解是DFS 不良的唯一独立预测因素(风险比:5.85,95%置信区间:1.69-20.23)。
将儿科 DTC 分为≤14 岁和 15-18 岁年龄组没有任何长期预测价值。ATA 推荐的 18 岁截止点是合理的,应该统一遵循,以避免不一致和混淆。